S. Berry

发表

Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo

B. Roth, L. Friedman, E. sanders-Bush, 1999, Neuroscience.

Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.

R. Ganguli, J. Brar, G. Pandina, 2005, The Journal of clinical psychiatry.

Effect of D2 dopamine agonists on tuberoinfundibular dopamine neurons

S. Berry, G. Gudelsky, 1991, Neuropharmacology.

Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.

J. Lindenmayer, S. Berry, M. Eerdekens, 2004, The Journal of clinical psychiatry.

Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study

D. Palumbo, P. Chappell, S. Wigal, 2018, Journal of child and adolescent psychopharmacology.

Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder

J. Orazem, D. Palumbo, P. Chappell, 2017, Journal of child and adolescent psychopharmacology.

Single-Dose Pharmacokinetics of NWP06, an Extended-Release Methylphenidate Suspension, in Children and Adolescents with ADHD

F. Sallee, S. Berry, A. Childress, 2011, Postgraduate medicine.

The Single-Dose Pharmacokinetics of NWP06, a Novel Extended-Release Methylphenidate Oral Suspension

S. Berry, A. Childress, 2010, Postgraduate medicine.

Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole.

D. Palumbo, R. Abbas, S. Berry, 2018, Clinical therapeutics.

Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet.

D. Palumbo, R. Abbas, S. Berry, 2016, Clinical therapeutics.

Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended‐Release Oral Suspension for Attention Deficit Hyperactivity Disorder

D. Palumbo, F. Sallee, R. Abbas, 2017, Clinical pharmacology in drug development.

NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.

S. Wigal, S. Berry, A. Childress, 2013, Journal of child and adolescent psychopharmacology.

Basic biology of clozapine: electrophysiological and neuroendocrinological studies

H. Meltzer, S. Berry, G. Gudelsky, 2004, Psychopharmacology.

D1 receptors function to inhibit the activation of tuberoinfundibular dopamine neurons.

S. Berry, G. Gudelsky, 1990, The Journal of pharmacology and experimental therapeutics.

Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity.

R. Eckel, J. Auwerx, M. D. Leibowitz, 2001, Molecular pharmacology.

Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation.

B. Roth, W. Kroeze, K. Kristiansen, 1998, Critical reviews in neurobiology.

Serotonergic Antagonist Effects on Trafficking of Serotonin 5‐HT2A Receptors in Vitro and in Vivo a

B. Roth, L. Friedman, E. sanders-Bush, 1998, Annals of the New York Academy of Sciences.

Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro.

B. Roth, S. Berry, N. Khan, 1996, Molecular pharmacology.

Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone concentrations in the rat.

H. Meltzer, S. Berry, G. Gudelsky, 1989, Neuroendocrinology.

Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD

R. Findling, S. Wigal, S. Berry, 2017, Journal of attention disorders.

Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study

R. Ganguli, J. Brar, G. Pandina, 2008, BMC medicine.

Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.

R. Bergman, C. Nemeroff, L. Phillips, 2008, Journal of psychiatric research.

Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder

S. Wigal, M. Brams, S. Berry, 2017, Journal of child and adolescent psychopharmacology.

Evidence for protein kinase-C mediation of the neurotensin-induced activation of tyrosine hydroxylase in tuberoinfundibular dopaminergic neurons.

S. Berry, G. Gudelsky, 1992, Endocrinology.

Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia

J. Jesberger, S. Berry, K. L. Camlin, 1999, Biological Psychiatry.

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

S. Berry, Ann C. Childress, Sally A. Berry, 2012, Drugs.

5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation.

B. Roth, S. Berry, M. S. Choudhary, 1995, The Journal of pharmacology and experimental therapeutics.

Recurrent priapism during treatment with clozapine and olanzapine.

M. Compton, S. Berry, A. Saldivia, 2000, The American journal of psychiatry.

Actions of typical and atypical antipsychotics on tuberoinfundibular dopamine neurons.

H. Meltzer, S. Berry, G. Gudelsky, 1989, Psychopharmacology bulletin.

The Single-Dose Pharmacokinetics of NWP06, a Novel Extended-Release Methylphenidate Oral Suspension

S. Berry, A. Childress, 2010, Postgraduate medicine.